Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical Company has discontinued clinical development for its investigational compound TAK-379, a treatment of diabetes.
Subscribe to our email newsletter
According to Takeda, TAK-379 is an anti-diabetic agent categorized as an insulin sensitizer and was in the Phase II stage of development in the US and Europe, and in the Phase I stage of development in Japan, respectively. However, the company has concluded that TAK-379’s profile does not meet the internal criteria to support continuation of further development activities.
The company said that it will continue to work for enhancing its R&D pipeline through in-house R&D activities; supported by in-licensing and alliance activities and product life cycle management; pursuing the earliest possible submission and approval of the mainstay products of the next generation which are in the late clinical development stage.